Laurus Labs gains 2% on robust growth outlook, zooms 70% so far in FY22

The company is looking to build new capacities and facilities that would propel its growth in the coming years

Shares of Laurus Labs traded 2 per cent higher at Rs 615.40 on the BSE in intra-day trade on Tuesday, rising 70 per cent thus far in the current financial year 2021-22 (FY22) on a robust growth outlook. In comparison, the S&P BSE Sensex is up 7 per cent since April. The stock of the pharmaceutical company had hit a record high of Rs 641.95 on June 8, 2021. 

Laurus Labs is a leading developer and manufacturer of generic APIs (active pharmaceutical ingredient) with a focus on products where it has cost leadership and holds an advantage by way of